Lattice Biologics closed a private placement for gross proceeds of up to US $0.75MM to fund M&A and the acquisition of donors to support production of an amniotic fluid product for regenerative use. The novel regenerative therapeutic will target osteoarthritis, spine, sports-medicine, foot/ankle and other indications. 

Strategic orthopaedic-related 510(k)s issued in August 2016 include: Xycor Expandable Spinal Spacer (Alphatec Spine); Valeo II Interbody Fusion Device (Amedica); Tarsa-Link Standalone Wedge, Hammertoe Correction System (Centric Medical/Life Spine); Universal Spine System (Double Medical Technology); Titan Reverse Shoulder (Integra LifeSciences); Virtu Lumbar Spacer (Met 1 Technologies*); Distal Radius Plating System (Miami Device Solutions); Response BandLoc Spinal Fixation (OrthoPediatrics)

Contact Us